BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10660737)

  • 41. [Raltitrexed in colorectal cancer].
    Comandone A; Oliva C; Dal Canton O; Boglione A; Bergnolo P
    Tumori; 2001; 87(1 Suppl 1):S53-4. PubMed ID: 11300026
    [No Abstract]   [Full Text] [Related]  

  • 42. Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers: a phase I study.
    Valentini V; Doglietto GB; Morganti AG; Turriziani A; Smaniotto D; De Santis M; Ratto C; Sofo L; Cellini N
    Eur J Cancer; 2001 Nov; 37(16):2050-5. PubMed ID: 11597383
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Raltitrexed (Tomudex) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies.
    James R; Price P; Valentini V
    Eur J Cancer; 1999 Mar; 35 Suppl 1():S19-22. PubMed ID: 10645210
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug resistance in colon cancer.
    Gorlick R; Bertino JR
    Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.
    Cunningham D; Zalcberg J; Maroun J; James R; Clarke S; Maughan TS; Vincent M; Schulz J; González Barón M; Facchini T
    Eur J Cancer; 2002 Mar; 38(4):478-86. PubMed ID: 11872339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens.
    Blay JY; Judson I; Rodenhuis S; Hermans C; Smith M; van Glabbeke M; Verweij J
    Anticancer Drugs; 1999 Nov; 10(10):873-7. PubMed ID: 10630354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer.
    Batra A; Rigo R; Hannouf MB; Cheung WY
    Clin Colorectal Cancer; 2021 Jun; 20(2):e75-e81. PubMed ID: 33268287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.
    Woll PJ; Basser R; Le Chevalier T; Drings P; Perez Manga G; Adenis A; Seymour L; Smith F; Thatcher N
    Br J Cancer; 1997; 76(2):264-5. PubMed ID: 9231930
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 'Tomudex' (raltitrexed) development: preclinical, phase I and II studies.
    Judson IR
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S5-9. PubMed ID: 9376637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer.
    Zalcberg J
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S17-22. PubMed ID: 9376633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A phase II study of ranomustine (MCNU) tablets in patients with gastrointestinal cancer--by cooperative study group].
    Taguchi T
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2420-6. PubMed ID: 6497400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Irinotecan and tomudex in the treatment of patients with advanced cancer of the large intestine].
    Reutova EV
    Vopr Onkol; 2001; 47(6):731-5. PubMed ID: 11826499
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.
    Shen J; Wang H; Wei J; Yu L; Xie L; Qian X; Zou Z; Liu B; Guan W
    Int J Cancer; 2012 Sep; 131(6):E938-45. PubMed ID: 22422354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical trials referral resource. Clinical trials with tomudex.
    Sorensen JM; Cheson BD; Phillips PH
    Oncology (Williston Park); 1996 Jul; 10(7):1041-2. PubMed ID: 8837120
    [No Abstract]   [Full Text] [Related]  

  • 55. Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
    Osterlund P; Orpana A; Elomaa I; Repo H; Joensuu H
    Br J Cancer; 2002 Sep; 87(6):591-9. PubMed ID: 12237767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
    Lynch G; Kemeny N; Casper E
    Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vindesine in the treatment of advanced colorectal cancer: a phase II study.
    Diaz-Rubio E; Martin-Jimenez M
    Cancer Treat Rep; 1984 Mar; 68(3):555-6. PubMed ID: 6704985
    [No Abstract]   [Full Text] [Related]  

  • 58. Phase II evaluation of 4'-epi-doxorubicin in patients with advanced colorectal carcinoma.
    Michaelson R; Kemeny N; Young C
    Cancer Treat Rep; 1982 Sep; 66(9):1757-8. PubMed ID: 6956441
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
    Cunningham D; Zalcberg J; Smith I; Gore M; Pazdur R; Burris H; Meropol NJ; Kennealey G; Seymour L
    Ann Oncol; 1996 Feb; 7(2):179-82. PubMed ID: 8777175
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Raltitrexed, a new drug for advanced colorectal cancer.
    Mead GM
    Lancet; 1996 Jun; 347(9015):1568-9. PubMed ID: 8667859
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.